Reviewer's report

Title: Carmustine (BCNU) for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

Version: 3 Date: 27 August 2009

Reviewer: Renato v La Rocca

Reviewer's report:

The revised manuscript is improved. The authors have appropriately addresssed the concerns raised by the various reviewers. There are a few discretionary stylistic alternatives that can be considered.

Page 2 Paragraph 2, line 2 "treated with BCNU 80 mg/m2 intravenously on days 1-3 at our..."
Page 2, third line from the bottom - "or the intensified temozolomide regimen"
Page 11 Paragraph 2, third line - "can be administered as an outpatient."
Page 12, Paragraph 3, lines 9-12 - "was terminated due to radiographic progression of disease without... be in some cases treatment related and not true objective tumor progression... has not been described in the literature to date and therefore...
Page 13, paragraph 2 Sentence 3 is too long. Suggest: "However, one limitation of this study is the missing information about the status of MGMT promoter methylation. Molecular studies have demonstrated that..."
Page 13, paragraph 3, line 12 - "epigenetic characterization of of gliomas is essential in future glioma therapy"
Page 13 paragraph 3, line 14 - "One concept is to irreversibly inactivate MGMT.."

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.